Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 0 · 0%High 1 · 50%

Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab showed no clear difference in myocardial infarction compared with ezetimibe and statins (low certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 1.45 [0.64, 3.28]
5 studies · 1734 participants
Low

Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)

Alirocumab leads to lower myocardial infarction compared with placebo (high certainty).

1 finding from 1 review

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease 2020 · Cochrane Headline outcomes only
OR 0.86 [0.79, 0.94]
9 studies · 23352 participants
High